BIIB · News · 20260809N
Revenue Performance and Mix
BIOGEN INC. · 2026-08-09 · Importance 17 · Surprise 24
Biogen reported higher revenue in the second quarter of 2026, supported by newer therapies and the Apellis acquisition. Net income and diluted EPS declined materially despite the revenue increase. The results indicate profitability pressure during Biogen’s transition from legacy products toward a broader neurology and rare-disease portfolio.